Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 11 - 20 of about 81   

Articles published

ARNA 4.20 -0.04 (-0.94%)
price chart
Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch Health ...
SAN DIEGO, May 8, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. ARNA, -0.46% announced today that the company is scheduled to present a corporate overview and update at the Bank of America Merrill Lynch 2015 Health Care Conference on ...
Arena: Television Advertising Sees Better Metrics - Be Cautious Though (ARNA)
If Arena (NASDAQ:ARNA) investors were to list a major complaint about the television advertising campaign, the list would include the airing of advertisements in the middle of the night, a lack of consistency, and too few prime time airings.
Eisai and Arena Pharmaceuticals Announce Presentation of Lorcaserin HCl ...
Eisai Inc. has affiliates that are part of a global product creation organization that includes R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as a global demand chain organization that includes manufacturing ...
Arena - Flatness In Scripts Will Impact The Equity
Arena Pharmaceuticals (NASDAQ:ARNA) has seen sales of the anti-obesity drug Belviq flatten out over the past few weeks while competitor Contrave from Orexigen (NASDAQ:OREX) continues to close the gap.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Releases Favorable Results ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) released favorable results from a Phase 1 single-ascending dose clinical trial of APD371, a highly selective and potent agonist of the cannabinoid 2 or CB2 receptor currently in development for the treatment of ...
Arena: Belviq Scripts Pop, Recover From Previous Dip
Arena Pharmaceuticals (NASDAQ:ARNA) investors had something to smile about when script numbers for the week ending April 17th were released today.
Biotech Stocks Getting No Love - Merrimack Pharmaceuticals (MACK), Arena ...
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) fell -2.14% to close last trading session at $12.79. The company, on May 14, 2015, declared that data supporting further research and clinical development of MM-398 will be presented at the 2015 American ...
Active Watch List: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) belongs to Healthcare sector. Its weekly performance is 1.65%. On last trading day company shares ended up $4.31.
Trader's Recap: The Gap, Inc. (NYSE:GPS), Arena Pharmaceuticals, Inc ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares decreased -1.05% in last trading session and ended the day at $4.25.
Short Interest in Arena Pharmaceuticals Declines By 11.8% (ARNA)
Arena Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors.